September 14, 2023 – Brandywine Global Investment Management LLC, a prominent investment management firm, has made headlines with its recent acquisition of a new position in shares of Organon & Co. (NYSE:OGN). According to the company’s filing with the Securities and Exchange Commission (SEC), Brandywine Global Investment Management LLC purchased 445,053 shares of Organon & Co., worth approximately $10,468,000 during the first quarter.
This move by Brandywine Global Investment Management LLC signifies its confidence in the future prospects of Organon & Co., a leading healthcare company that focuses on delivering innovative medicines to patients worldwide. The substantial investment made by Brandywine Global Investment Management LLC showcases its dedication to identifying opportunities for growth and value in the market.
As an investment management firm with a strong reputation for prudent decision-making, Brandywine Global Investment Management LLC’s purchase of a significant number of shares demonstrates faith in Organon & Co.’s potential to generate substantial returns for its investors. With this acquisition, Brandywine Global Investment Management LLC now owned approximately 0.17% of Organon & Co. at the end of the most recent quarter.
Moreover, Organon & Co. recently declared its quarterly dividend which will be paid out on September 14th. Shareholders who were recorded as investors on August 18th will receive a dividend of $0.28 per share. The ex-dividend date falls on August 17th. This represents an annualized dividend payout of $1.12 per share and a remarkable yield of 5.81%. These figures highlight Organon & Co.’s commitment to returning value to its shareholders through consistent dividends.
Organon & Co.’s prudent approach is evident from its current dividend payout ratio, standing at 37.97%. This ratio indicates that the company allocates just under 38% of its net income towards distributing dividends to its investors. This balanced approach ensures that Organon & Co. remains financially stable while continuing to reward its dedicated shareholders.
As of our reference date, September 14, 2023, the recent acquisition by Brandywine Global Investment Management LLC and the declaration of a quarterly dividend by Organon & Co. reflect the positive outlook surrounding the company’s future growth. Investors and market analysts will undoubtedly keep a close eye on these developments as they navigate their investment strategies in an ever-evolving financial landscape.
Disclaimer: Our analysis is driven by publicly available information and should not be considered as investment advice. It is important to conduct thorough research and seek guidance from financial professionals before making any investment decisions.
[bs_slider_forecast ticker=”EQH”]
CIBC World Markets Corp and Other Institutional Investors Make Significant Changes to Holdings in Organon & Co.
Institutional investors and hedge funds have recently made significant changes to their holdings of Organon & Co., a pharmaceutical company operating in the global healthcare industry. Cibc World Markets Corp, for example, acquired a new position in shares of the company during the fourth quarter, amounting to $835,000. State of Michigan Retirement System also increased its stake in Organon & Co. by 1.0% in the first quarter, now owning 69,864 shares valued at $1,643,000 after acquiring an additional 700 shares.
Brown Advisory Inc., another institutional investor, boosted its stake in Organon & Co. by 4.3% in the first quarter. Currently owning 46,885 shares worth $1,103,000 after acquiring an additional 1,923 shares during this period. Whitener Capital Management Inc. joined the ranks of investors purchasing shares of Organon & Co., buying a new stake valued at approximately $243,000 during the fourth quarter. Lastly, Oppenheimer & Co. Inc. significantly raised its holdings in shares of Organon & Co. by 26.9% during the first quarter and now owns 117,944 shares valued at $2,774,000.
These actions by institutional investors and hedge funds have brought their ownership to roughly 77.08% of Organon & Co.’s stock.
Separately from these developments with institutional investors and hedge funds, Morgan Stanley recently updated its target price for Organon & Co.’s shares from $25.00 to $27.00 while maintaining an “equal weight” rating for the company.
As of September 14th , on NYSE (New York Stock Exchange), Organon & Co.’s stock opened trading at $19.27 per share with a market capitalization of $4.92 billion. The company has displayed a price-to-earnings (P/E) ratio of 6.53 and a price-to-earnings growth (P/E/G) ratio of 0.62, indicating promising financial performance in relation to its growth potential. Moreover, Organon & Co. has a beta value of 0.80, suggesting that the stock is less volatile than the overall market.
Notwithstanding its current stock price, Organon & Co.’s share value has experienced fluctuations over the past year, with its lowest point recorded at $18.87 and its highest at $32.43. The firm’s 50-day moving average price stands at $21.50, while its 200-day moving average price is slightly higher at $21.83.
Regarding its financial performance, Organon & Co. reported a remarkable earnings per share (EPS) of $1.31 for the most recent quarter ended on August 8th – surpassing analysts’ consensus estimate by $0.34 per share. Its revenue for the same period amounted to $1.61 billion, slightly exceeding previous expectations of around $1.57 billion.
With a net margin of 12.22% and a negative return on equity of 142.40%, Organon & Co.’s profitability indicators may be cause for concern among investors who closely follow these factors when evaluating potential investment opportunities.
Looking ahead, equities research analysts anticipate that Organon & Co’s earnings per share will reach approximately $4.29 for the current fiscal year.
In conclusion, Organon & Co., a pharmaceutical company operating in the global healthcare industry and listed as NYSE:OGN on the New York Stock Exchange, has recently witnessed significant changes in its holdings due to actions taken by institutional investors and hedge funds alike. These developments have garnered attention from major financial institutions such as Cibc World Markets Corp and State of Michigan Retirement System, which have increased their stakes in the company during different quarters. While financial data and performance indicators suggest promising signs, investors are advised to diligently analyze the potential risks and rewards associated with investing in Organon & Co.’s stock.
